Novavax, Inc. and FUJIFILM Diosynth Biotechnologies (FDB), a contract development and manufacturing organization for biologics, viral vaccines and gene therapies, entered an agreement to manufacture bulk drug substance for NVX-CoV2373, Novavax’ COVID-19 vaccine candidate. FDB’s site in Morrisville, NC has begun production of the first batch of NVX-CoV2373.  This agreement falls under Novavax’ recent $1.6 billion award by the federal government as part of the Operation Warp S...